PROJECT SUMMARY/ABSTRACT
The overall objective of the Clinical Isolate Core (Core B) is to provide access to a robust collection of clinical
bacterial isolates and a standardized and experimentally controlled platform for evaluating antibiotic
heteroresistance (HR) for the Heteroresistance Interdisciplinary Research Unit (HR-IRU). Core B is therefore
essential to the overall success of the HR-IRU program. To accomplish Core goals, we have assembled a
multidisciplinary team including an infectious disease clinician (Jacob), a research scientist (Satola), a board-
certified medical microbiologist (Burd) and an epidemiologist (Tunali) with expertise vast areas of antibiotic
resistance. For Core B to enable successful completion of the research projects and advance our understanding
of antibiotic HR we propose three specific aims. 1) To provide access to clinical bacterial isolate. Isolates
(Enterobacterales and Acinetobacter baumanii complex) will be collected as part of the Centers for Disease
Control and Prevention's (CDC) Georgia Emerging Infections Program (EIP) Multi-site Gram-negative
Surveillance Initiative (MuGSI), Emory University's Investigational Clinical Microbiology Core (ICMC)
biorepository, and Uppsala University Hospital, Sweden. 2) To profile clinical bacterial isolates for HR. We will
test 500 bacterial isolates per year from bloodstream, urine, and respiratory clinical infections: 200 multi-drug
resistant organisms (MDRO) from the Georgia EIP; 100 non-MDRO from the ICMC and 200 predominately
susceptible isolates from Uppsala University Hospital, Sweden. Each isolate will be tested for HR to
approximately 20 antibiotics using population analysis profiling (PAP), the gold standard for HR. 3) To perform
epidemiological analyses revealing the prevalence, type and trends of HR. We will establish the prevalence of
HR from the 2500 isolates tested in aim 2. We will perform comprehensive descriptive epidemiology on the
clinical and laboratory characteristics of isolates with HR and compare those to isolates without HR. Core B will
be conducted in the laboratories of the Georgia EIP and Emory University's ICMC, which have extensive
expertise in active-population based surveillance and studies of HR. The Core leadership will work closely with
the HR-IRU program directors/PIs and project leaders to ensure that the needs of all projects are rigorously met
in a reliable, reproducible and timely manner.
Public Health Relevance Statement
PROJECT NARRATIVE
In accordance with RFA-AI-20-001, the project narrative should not be completed for the scientific core.
NIH Spending Category
No NIH Spending Category available.
Project Terms
AcinetobacterAcinetobacter baumanniiAgeAntibiotic ResistanceAntibioticsAreaBlood CirculationBoard CertificationCenters for Disease Control and Prevention (U.S.)CharacteristicsClinicalClinical MicrobiologyCollectionCommunicable DiseasesComplexDataDescriptive EpidemiologyEmerging infectionEnterobacterEnterobacteriaceaeEpidemiologistEpidemiologyEscherichiaFundingGeneticGenotypeGoalsHealthcareInfectionInterdisciplinary StudyIntermediate resistanceKlebsiellaKnowledgeLaboratoriesLeadershipLinkMedicalMedical DeviceMetabolicMethodologyMethodsPatient CarePatternPopulation AnalysisPredispositionPrevalenceProcessPublicationsRaceReproducibilityResearchResearch Project GrantsRisk FactorsScientistSiteStandardizationSwedenSyndromeTestingUniversitiesUniversity HospitalsUrineWorkbiobankcarbapenem resistancelongitudinal analysismulti-drug resistant pathogenmultidisciplinarynoveloperationpopulation basedprogramsprospectiveprospective testrespiratorysexstatisticssuccesstrend
National Institute of Allergy and Infectious Diseases
CFDA Code
DUNS Number
066469933
UEI
S352L5PJLMP8
Project Start Date
05-March-2021
Project End Date
28-February-2026
Budget Start Date
01-March-2024
Budget End Date
28-February-2025
Project Funding Information for 2024
Total Funding
$406,982
Direct Costs
$241,391
Indirect Costs
$165,591
Year
Funding IC
FY Total Cost by IC
2024
National Institute of Allergy and Infectious Diseases
$406,982
Year
Funding IC
FY Total Cost by IC
Sub Projects
No Sub Projects information available for 5U19AI158080-04 5645
Publications
Publications are associated with projects, but cannot be identified with any particular year of the project or fiscal year of funding. This is due to the continuous and cumulative nature of knowledge generation across the life of a project and the sometimes long and variable publishing timeline. Similarly, for multi-component projects, publications are associated with the parent core project and not with individual sub-projects.
No Publications available for 5U19AI158080-04 5645
Patents
No Patents information available for 5U19AI158080-04 5645
Outcomes
The Project Outcomes shown here are displayed verbatim as submitted by the Principal Investigator (PI) for this award. Any opinions, findings, and conclusions or recommendations expressed are those of the PI and do not necessarily reflect the views of the National Institutes of Health. NIH has not endorsed the content below.
No Outcomes available for 5U19AI158080-04 5645
Clinical Studies
No Clinical Studies information available for 5U19AI158080-04 5645
News and More
Related News Releases
No news release information available for 5U19AI158080-04 5645
History
No Historical information available for 5U19AI158080-04 5645
Similar Projects
No Similar Projects information available for 5U19AI158080-04 5645